

Laura Hunter

Senior Associate
Washington, D.C.

Biography

Laura Hunter utilizes her familiarity with challenges in the health care industry to advise clients on navigating the complex regulatory requirements of federal health care programs.

Laura's focus is on compliance with federal and state anti-kickback statutes, false claims laws, and the Civil Monetary Penalties Law. She works with drug and device manufacturers to design, implement, and improve compliance programs, policies, and procedures. She advises on the structure and implementation of patient support programs, product support services, and charitable donations. Laura is an authority on the Physician Payments Sunshine Act, analogous state transparency laws, and state pharmaceutical and device marketing laws. When things don't go according to plan, Laura helps companies conduct internal investigations, decide on appropriate corrective actions, respond to wide-ranging government investigations, and defend against enforcement actions.

Laura also regularly advises clients on coverage and reimbursement of new technologies, assists clients in addressing Medicare and Medicaid billing issues, and advises on complex regulatory issues in areas such as telehealth, personalized medicine, and digital health.

Her clients span the health care industry, including drug and device manufacturers, managed care plans, health information technology companies, and other health care providers.



Phone

+1 202 637 7723

Fax

+1 202 637 5910

Email

laura.hunter@hoganlovells.com

Practices

Health

Industries

Life Sciences and Health Care

Education and admissions

Education

J.D., New York University School of Law, Order of the Coif, 2016

M.A., The University of Georgia, 2010

B.A., The University of Georgia, summa cum laude, 2010

Laura received her J.D. from the New York University School of Law, where she served as an Executive Editor on the *Journal of Legislation and Public Policy*. As a law student, Laura received the John J. Creedon Scholarship.

Bar admissions and qualifications

District of Columbia

Latest thinking and events

- News
 - OIG's first-ever General Compliance Program Guidance covering all health care parties released
- News
 - New Connecticut rules for drug makers employing sales reps take effect Oct. 1
- News
 - Sixth Circuit weighs in on meaning of causation, remuneration for False Claims based on alleged kickbacks
- News
 - New circuit split on evidence needed to prove a kickback renders a claim false or fraudulent
- News
 - OIG green lights drug manufacturer-sponsored genetic testing program
- News
 - Reminder: New Oregon licensure requirements for pharma sales reps now in effect!